Roche’s Evrysdi offers sustained benefits in SMA extension trial in children

Roche has announced five-year findings from the open-label extension portion of the FIREFISH study, where Evrysdi (risdiplam) offered sustained efficacy and safety in children with type 1 spinal muscular atrophy (SMA).